Condition: Head and Neck Squamous Cell Carcinoma · Soft Tissue Sarcoma Adult · Triple Negative Breast Cancer · Sponsor: Pure Biologics S.A.
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in microdose quantities via the CIVO device.
This description comes directly from the study's public registry record.
Presage Biosciences · 800-530-5404 · clinops@presagebio.com
Always discuss trial participation with your own doctor first.
| LSU Health Sciences Center | Shreveport, Louisiana, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06700070